)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Gedeon Richter
Gedeon Richter (RICHTER) investor relations material
Gedeon Richter Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary7 Aug, 2026
Executive summary
H1 2026 CER revenue grew 8.7%, with double-digit Q2 top-line growth; reported revenues declined 0.8% YoY due to strong HUF FX headwind.
CER Clean EBIT up 21% YoY, driven by CNS and BIO segments, and lower opex; reported Clean EBIT up 3% YoY.
Net profit fell 14% YoY to HUF 103.5bn, mainly due to significant FX losses despite resilient operating profit.
Free cash flow reached a record HUF 137bn in H1 2026, up 24% YoY, supported by lower net working capital needs and higher operating profits.
Key launches included Fylrevy® (menopause therapy) and Tuyory® (biosimilar tocilizumab); CNS pipeline advanced with RGH-202 entering Phase II.
Financial highlights
Pharma revenues at HUF 461,596m (EUR 1,228mn) in H1 2026; Clean EBIT at HUF 151.8bn (EUR 407mn).
Gross profit (pharma) fell 2.3% YoY to HUF 316,799m; gross margin declined to 68.6%.
Return on equity at 15.8%, down 1.2ppt YoY.
EPS at HUF 566, down 13.7% YoY.
EBIT margin at 31.1%.
Outlook and guidance
Pharma CER revenue guidance maintained at high-single-digit growth for 2026.
Pharma Clean EBIT (CER) guidance upgraded to double-digit growth for 2026.
Continued focus on innovative portfolio expansion and operational efficiency.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gedeon Richter
- Strong H1 2026 growth, innovation pipeline, and sustainability drive long-term value.RICHTER
Investor presentation7 Aug 2026 - Strong Q1 growth, record cash flow, and four biosimilar launches planned in next 12 months.RICHTERQ1 20258 Jul 2026
- Acquisitions and innovation accelerate growth toward European leadership in women’s healthcare.RICHTERInvestor Update8 Jul 2026
- Strong 2025 results with robust growth in Women's Health and innovation, outlook remains positive.RICHTERQ4 202515 May 2026
- Revenue up 10.9–11%, Clean EBIT up 14.5–15.1%, but net profit down 13.2%.RICHTERQ2 202515 May 2026
- Record 2024 growth and cash flow; 2025 targets 10% gains with cost and R&D focus.RICHTERQ4 202415 May 2026
- Q1 2026 delivered 5.9% CER growth, 15% EBIT rise, but FX and net profit declines persisted.RICHTERQ1 202612 May 2026
- Women's Healthcare and Biotech drive growth as Vraylar® and biosimilars outperform in Q1 2026.RICHTERInvestor presentation12 May 2026
- 2025 saw double-digit EBIT growth, strong cash flow, and strategic expansion in WHC and Biotech.RICHTERInvestor presentation27 Feb 2026
Next Gedeon Richter earnings date
Q3 202610 Nov, 2026
Gedeon Richter
Next Gedeon Richter earnings date
Q3 202610 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage